The Role of High Dose Rate Brachytherapy in the Palliation of Symptom in Patients with Non-Small Cell Lung Cancer Evidence-based Series 7-16 Version 4 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of High Dose Rate Brachytherapy in the Palliation of Symptoms in Patients with Non-Small Cell Lung Cancer Members of the Lung Cancer : ccopgi@mcmaster.ca PEBC Report Citation (Vancouver Style): Ung Y, Yu E, Falkson C, Haynes A, Evans WK; Lung Cancer Disease Site Group. The role of high dose rate brachytherapy in the palliation of symptoms in patients with non-small cell lung cancer. Falkson C, Arinze C, reviewers. Toronto (ON): Cancer Care Ontario; Endorsed 2022 Dec 16. Program in Evidence-based Care Evidence-based Series No.: 7-16
Rhenium-188 Brachytherapy for non-melanoma skin cancer 1 Medical Services Advisory Committee (MSAC) Public Summary Document Application No. 1657 – Rhenium-188 brachytherapy for non-melanoma skin cancer Applicant: OncoBeta Therapeutics Australia Pty Ltd Date of MSAC consideration: 27 July 2023 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefits Schedule (MBS) listing of high-dose brachytherapy with Rhenium-188 (Re-188) for patients with certain keratinocyte cancers was received from OncoBeta Therapeutics Australia Pty Ltd by the Department of Health and Aged Care. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation
Low energy contact X-ray brachytherapy (CXB) for the treatment of early stage rectal cancer Low energy contact X-ray brachytherapy (CXB) - Health Technology Wales AAA * * About us * * View About us * About HTW * Our Groups & Forums * * Executive Group * Appraisal Panel * Assessment Group * Patient and Public Involvement Standing Group * Industry * Videos * Workshops * Reports & Guidance * Publications * * View Publications * Quarterly Bulletin * Adoption Audit * Annual Report * HTW Strategic Plan * Evaluation Strategy * Communications Strategy * News & Events SearchContactCymraegAAAReports & Guidance > Low energy contact X-ray brachytherapy (CXB)Low energy contact X-ray brachytherapy
Permanent implant brachytherapy devices for unresectable pancreatic cancer AAAReports & Guidance > Permanent implant brachytherapy devices for unresectable pancreatic cancerPermanent implant brachytherapy devices for unresectable pancreatic cancerTOPIC STATUS Incomplete Pancreatic cancer is the 10th most common cancer in the UK and is often diagnosed at a stage when surgery is not possible.Brachytherapy is a type of internal radiotherapy which may be an effective option for the treatment of locally advanced unresectable pancreatic cancer.Summary Health Technology Wales researchers searched for evidence on the clinical and cost effectiveness of permanent implant brachytherapy devices for the treatment of unresectable locally advanced pancreatic cancer.Topic Exploration ReportTER503
Appropriate Use Criteria: Brachytherapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, and Stereotactic Radiosurgery 8600 West Bryn Mawr Avenue South Tower – Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable Effective Date: 11/06/2022 Version Creation Date: 05/09/2022 Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details. AIM Specialty Health disclaims any responsibility for the completeness or accuracy of the information contained herein. CLINICAL APPROPRIATENESS GUIDELINES RADIATION ONCOLOGY Appropriate Use Criteria: Brachytherapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, and Stereotactic Radiosurgery
Guidelines for permanent iodine-125 seed interstitial brachytherapy for pancreatic cancer (2023 edition): The Chinese expert consensus workshop report The incidence of pancreatic cancer is increasing worldwide. Approximately, 60% of patients with pancreatic cancer have distant metastases at the time of diagnosis, of which only 10% can be removed using standard resection. Further, patients derive limited benefits from chemotherapy or radiotherapy. As such, alternative methods to achieve local control have emerged, including permanent iodine-125 seed interstitial brachytherapy. In 2023, the Chinese College of Interventionalists, affiliated with the Chinese Medical Doctor Association, organized a group of multi-disciplinary experts to compose guidelines for this treatment modality. The aim
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer Interventional procedures guidance Published: 14 August 2019 www.nice.org.uk/guidance/ipg659 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page. 1.2 Further research should include randomised controlled trials comparing this procedure with standard care
Japanese Society for Radiation Oncology Consensus Guidelines of combined intracavitary and interstitial brachytherapy for gynecological cancers It has been postulated that the combination of intracavitary and interstitial brachytherapy (IC/IS) is effective and safe for large and irregularly shaped uterine cervical cancer patients. However, due to its invasiveness compared to conventional intracavitary brachytherapy (ICBT), it has to be said that the implementation speed of IC/IS is slow. Until now, there have been no guidelines for required equipment, human resources, and procedural guide focusing solely on IC/IS. The purpose of this guideline is to provide radiation oncologists and medical physicists who wish to start IC/IS with practical and comprehensive guidance for a safe IC
Appropriate Use Criteria: Brachytherapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, and Stereotactic Radiosurgery 8600 West Bryn Mawr Avenue South Tower – Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable CLINICAL APPROPRIATENESS GUIDELINES RADIATION ONCOLOGY Appropriate Use Criteria: Brachytherapy, Intensity Modulated
Brachytherapy dose escalation with external beam radiotherapy for intermediate and high-risk localised prostate cancer NHS England » Brachytherapy dose escalation with external beam radiotherapy for intermediate and high-risk localised prostate cancer Skip to main content Cookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work.We’d also with external beam radiotherapy for intermediate and high-risk localised prostate cancerDocument first published: 7 July 2021 Page updated: 12 July 2021 Topic: Specialised commissioning Publication type: Policy or strategy Brachytherapy dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer is recommended as a routine commissioning treatment option within
Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer 1 Public Summary Document Application No. 1525 - Low dose-rate (LDR) brachytherapy for intermediate and high-risk prostate cancer Applicant: BXTAccelyon Australia Pty Ltd Date of MSAC consideration: MSAC 76th Meeting, 1-2 August 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefits Schedule (MBS) listing of LDR Brachytherapy (LDR-BT) for intermediate and high-risk prostate cancer was received from MedTechnique on behalf of BXTAccelyon Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence
GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR www.thegreenjournal.comVerify you are human by completing the action below.www.thegreenjournal.com needs to review the security of your connection before proceeding.Ray ID: 8d29e6d46d6c63f0Performance & security by Cloudflare
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial To determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer. Men
Brachytherapy in head and neck malignancies: Indian Brachytherapy Society (IBS) recommendations and guidelines Brachytherapy (BT) forms major treatment modality in squamous cell carcinoma of head and neck cancers (HNC). However, there is a dearth of literature and guidelines for the use in various indications. High-dose-rate brachytherapy (HDR-BT) in Indian scenario is an important treatment modality, and the recommendations in this guidelines aim to provide the necessary recommendations for the use of HDR-BT for uniform application across the country in patients with HNC. A panel consisting of members of the Indian Brachytherapy Society (IBS), based on their clinical experience was invited. The process involved defining important steps, precautions, target volumes and indications, thorough
A dosimetric comparison of brachytherapy sources for endometrial cancer: an electronic brachytherapy and an iridium-192 source with multichannel cylinders and a three-dimensional technique. Ir192 vaginal brachytherapy (IBT) is commonly used for patients with postoperative endometrial cancer (EC). We devised a novel multichannel vaginal applicator that could be equipped with an electronic brachytherapy (EBT) device. We aimed to explore the differences in physical parameters between the EBT and IBT. This retrospective study included 20 EC patients who received adjuvant IBT from March 1, 2023, to May 1, 2023. Multichannel vaginal cylinders were used, and three-dimensional plans were generated. We designed an electronic multichannel vaginal applicator model and simulated a three-dimensional EBT
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group. To report the results of a multicenter cohort of preoperative brachytherapy (PBT) for treatment of early-stage cervical cancer (ESCC). A retrospective analysis was conducted among five French comprehensive cancer centers on behalf of the SFRO Brachytherapy Group to examine the outcome of patients with ESCC who received PBT between 2001 and 2019 because of adverse prognostic factors (tumor size >2 cm, presence of lymphovascular invasion, adenocarcinoma).Brachytherapy was followed 4-8 weeks later by surgery. Local relapse free, distant metastasis-free survival, disease-free, and overall survival and adverse effects were examined. Uni- and multivariate analyses were conducted looking
Image-guided brachytherapy for pediatric bladder and/or prostate rhabdomyosarcoma: toward an increased personalization of treatment.: Brachytherapy in uro-pediatric rhabdomyosarcoma. Rhabdomyosarcoma (RMS) is the most common soft tissue cancer in children. Around 15% of RMS involve the bladder and/or prostate (BP). Overall survival is around 85%. After chemotherapy, patients receive local treatment based on surgery and/or radiotherapy. In recent decades, image guidance and pulsed dose-rate (PDR) brachytherapy have made it possible to personalize treatment, reduce radiation-related toxicity, while maintaining a good tumor control. We report one of the largest series of image-guided brachytherapy for pediatric RMS BP. The clinical and dosimetric parameters of children treated
GEC-ESTRO (ACROP)'ABS'CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina www.redjournal.orgChecking if the site connection is securewww.redjournal.org needs to review the security of your connection before proceeding.Ray ID: 7c9a8d2d29294072Performance & security by Cloudflare
Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality
High dose rate 192Ir brachytherapy source model Monte Carlo dosimetry: mHDR-v2 and mHDR-v2r. After 2010, the source model of the microSelectron HDR Afterloader System was slightly modified from the previous model. Granero et al. named the modified source model "mHDR-v2r (revised model mHDR-v2)" and the previous model "mHDR-v2". They concluded that the dosimetric differences arising from